In the UK, the National Health Service (NHS) is advised by, amongst others, The National Institute for Health and Care Excellence (NICE), who provide national guidance and advice to improve health and social care, have updated guidelines on two pathways that recommend treatments for reflux diseases. Both highlight IQoro as a treatment:
– Managing gastro-oesophageal reflux disease in adults (IQoro referenced under ‘Self-management advice’)
– Managing gastro-oesophageal reflux and reflux disease in children and young people (IQoro referenced under ‘Treatments’)
IQoro as an alternative to treat reflux diseases
Terry Morris, Director of Business Development at MYoroface describes the problem:
–The recommended treatments in the NHS include medication – which reduces the symptoms of reflux but does not address the underlying cause of the condition, and surgical operation which does treat the underlying cause by restructuring weakened musculature in the diaphragm. IQoro fits neatly as an alternative to both. It allows the user to retrain and strengthen the delinquent muscle that permits the problem, but without an invasive surgical operation; and it is an alternative to long-term prescription of PPI medication to merely reduce the symptoms.
PPI medication is acknowledged to have negative side-effects in the long term, and surgery is both invasive and costly to perform, and often very difficult to schedule in the current pandemic circumstances.
MedTech Innovation Briefing for IQoro
IQoro is a neuromuscular training device which patients can self-administer to treat reflux diseases. Training with IQoro takes 90 seconds per day. The device was notified to the NHS in a MedTech Innovation Briefing (MIB 176) in 2019, as an alternative to medication or surgery. 50 000 people have now used IQoro to treat their condition.